The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.
Richard S. Finn
Consultant or Advisory Role - Pfizer (U)
Veronique Dieras
No relevant relationships to disclose
Karen A. Gelmon
No relevant relationships to disclose
Nadia Harbeck
No relevant relationships to disclose
Stephen E. Jones
Consultant or Advisory Role - Pfizer
Maria Koehler
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Miguel Martin
Consultant or Advisory Role - Amgen; Roche
Hope S. Rugo
Research Funding - Novartis; Pfizer
Seock-Ah Im
No relevant relationships to disclose
Masakazu Toi
Honoraria - Pfizer
Research Funding - Pfizer
Eric Roland Gauthier
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Xin Huang
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Sophia Randolph
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Dennis J. Slamon
Consultant or Advisory Role - Novartis; Sanofi
Stock Ownership - Amgen; Pfizer